Pharma Business - January 31, 2018
Novo Nordisk does not intend to make a revised proposal for Ablynx
The company notes the announcement of Sanofi’s agreed acquisition of Ablynx and confirms that it will not be making a revised proposal. On 8 January, Novo Nordisk announced its proposal to acquire Ablynx for up to EUR 30.50 per share in cash, consisting of EUR 28.00 upfront and EUR 2.50 in Contingent Value Rights. Novo Nordisk […]
Global report - January 29, 2018
Sanofi acquires Ablynx for 3.9 billion EUR
Sanofi will acquire the Belgian biotech company Ablynx for 3.9 billion euros ($4.8 billion), just a few days after the company turned down Novo Nordisk’s bid. The acquisition is Sanofi’s second major takeover deal this month following its acquisition of Bioverativ. “Since our founding in 2001, our team has been focused on unlocking the power of […]
